LEO Pharma A/S, a global leader in medical dermatology, is pleased to share that The Lancet, which is considered one of the ...

Delgocitinib cream is efficacious and well-tolerated for the treatment of adults with chronic hand eczema for up to 52 weeks.

Treatment with delgocitinib cream, a topical pan-Janus kinase inhibitor, resulted in a significant improvement in health-related quality of life in patients with moderate to severe chronic hand ...

Delgocitinib cream is a topical pan-Janus kinase (JAK) inhibitor for the treatment of moderate to severe CHE. It inhibits the activation of JAK-STAT signaling, which plays a key role in the ...

drug delgocitinib, saying it outperformed the only approved drug therapy for the condition in a phase 3 trial. LEO’s topical cream formulation of the pan-JAK inhibitor proved to be more ...

These results bring us one step closer towards establishing delgocitinib as a best-in-class innovative topical treatment for patients affected by this hard-to-treat disease." Further analysis will ...

symptoms of moderate to severe frontal fibrosing alopecia improved with topical delgocitinib. Medscape Medical News, October 02, 2024 Avoiding Common Diagnostic Errors in Primary Care Experts on ...

DELTA FORCE is the first head-to-head phase 3 trial comparing a systemic and investigational delgocitinib topical treatment for Chronic Hand Eczema (CHE).1 LEO Pharma A/S, a global leader in medical ...